Ikarian Capital »

Morphosys shares owned by Ikarian Capital

Quarter-by-quarter ownership of Morphosys (MOR) shares owned by Ikarian Capital from 13F filings

Historical chart of Ikarian Capital investment in Morphosys

Tip: Access up to 7 years of quarterly data

All positions including Morphosys held by Ikarian Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Morphosys by Ikarian Capital

Quarter filed Position value Share count Share price at filing
2023-12-31 $4.0M 400k 9.90

More positions owned by Ikarian Capital

Argenx Se Sponsored Adr (ARGX)
Krystal Biotech Call Option (KRYS)
Cytokinetics Com New (CYTK)
Alnylam Pharmaceuticals Call Option (ALNY)
Spdr Ser Tr S&p Biotech Put Option (XBI)
Crispr Therapeutics Namen Akt (CRSP)
Eli Lilly & Co. Put Option (LLY)
Sarepta Therapeutics (SRPT)
Prothena Corp SHS Call Option (PRTA)
Amylyx Pharmaceuticals (AMLX)
Nuvalent Inc-a (NUVL)
Immunovant (IMVT)
Crinetics Pharmaceuticals In (CRNX)
Soleno Therapeutics (SLNO)
Eyepoint Pharmaceuticals Com New (EYPT)

View all positions for Ikarian Capital

Top funds holding Morphosys

Kynam Capital Management
Point72 Asset Management
T. Rowe Price Associates
Logos Global Management
Caption Management
Ikarian Capital
TD Asset Management
Citadel Advisors
Millennium Management
Marshall Wace
Goldman Sachs Group
TIG Advisors
Cubist Systematic Strategies
Two Sigma Investments
Opaleye Management

View all funds holding Morphosys